Title : A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.

Pub. Date : 2020 Oct

PMID : 32608142






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In a limited sample size, MYC copy-number gain or gene amplification, a candidate predictive biomarker for alisertib, did not correlate with improved response numbers or patient outcomes. MLN 8237 MYC proto-oncogene, bHLH transcription factor Homo sapiens